Mark Austin Jensen

US Patent:

7511121, Mar 31, 2009

Filed:

Mar 11, 2002

Appl. No.:

10/096521

Inventors:

Barry G. W. Arnason - Chicago IL, US
Mark A. Jensen - Chicago IL, US
David M. White - Chicago IL, US

International Classification:

C07K 16/00

US Classification:

5303871

Abstract:

The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with FcγR and which allow for the inclusion and targeting of a second protein domain to cells expressing FcγR. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgGfused to the framework region of human IgG. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of FcγR in autoimmune disorders.

US Patent:

7897729, Mar 1, 2011

Filed:

Sep 18, 2008

Appl. No.:

12/212776

Inventors:

Barry G. W. Arnason - Chicago IL, US
Mark A. Jensen - Chicago IL, US
David M. White - Chicago IL, US

Assignee:

Iterative Therapeutics, Inc. - Chicago IL

International Classification:

C07K 16/00

US Classification:

5303871

Abstract:

The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with FcγR and which allow for the inclusion and targeting of a second protein domain to cells expressing FcγR. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgGfused to the framework region of human IgG. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fission proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of FcγR in autoimmune disorders.

US Patent:

8163289, Apr 24, 2012

Filed:

Mar 6, 2008

Appl. No.:

12/043769

Inventors:

Barry G. W. Arnason - Chicago IL, US
Mark A. Jensen - Chicago IL, US
David M. White - Chicago IL, US

Assignee:

Iterative Therapeutics, Inc. - Chicago IL

International Classification:

A61K 39/00
A61K 39/38
A61K 39/385

US Classification:

4241841, 4241851, 4241921, 4241931

Abstract:

The present invention concerns inventive polypeptides. The present invention also concerns compositions and vaccines comprising the inventive polypeptides. In other embodiments of the invention, the inventive polypeptides are provided to a subject, used to vaccinate, or used to induce immunity. Other embodiments include methods for making the inventive polypeptides and nucleic acids used to encode the inventive polypeptides.

US Patent:

20110195067, Aug 11, 2011

Filed:

Feb 12, 2011

Appl. No.:

13/026207

Inventors:

Barry G. W. Arnason - Chicago IL, US
Mark A. Jensen - Chicago IL, US
David M. White - Chicago IL, US

Assignee:

Iterative Therapeutics, Inc. - Chicago IL

International Classification:

A61K 39/395
C07H 21/00
C12N 5/071
C12N 15/63
A61P 37/02

US Classification:

4241331, 536 2353, 435325, 4353201

Abstract:

The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with FcγR and which allow for the inclusion and targeting of a second protein domain to cells expressing FcγR. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgGfused to the framework region of human IgG. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of FcγR in autoimmune disorders.

US Patent:

49288679, May 29, 1990

Filed:

Jun 30, 1989

Appl. No.:

7/376207

Inventors:

Mark B. Jensen - Mesa AZ

International Classification:

B25C 100
B25C 700

US Classification:

227 7

Abstract:

A connector (10) for positioning fasteners (16) in a preformed opening (24) in a wall (12). Tabs (18) formed on the front surface (13) of the wall (12) guide the nail gun (22) and trip a trigger mechanism to cause the fastener (16) to be driven through the wall (12) and into an abutting structural member. The system further includes a nail gun (59) having a follower plate (94) pivotally mounted in channels (89) formed on each side of a foot (79). Each follower plate (94) is guided into contact with a tab (116) that pivots the follower plate (94) into contact with a mounting plate (75) attached to a linking arm (68) that enables activation of a pneumatic nail driving device (62) and the ejection of a nail through a predetermined position on the connector (118).

US Patent:

20140087422, Mar 27, 2014

Filed:

Mar 10, 2013

Appl. No.:

13/792131

Inventors:

Iterative Therapeutics, Inc. - , US
Mark A. Jensen - Chicago IL, US
David M. White - Chicago IL, US

Assignee:

ITERATIVE THERAPEUTICS, INC. - Chicago IL

International Classification:

C07K 16/28
C07K 14/765

US Classification:

435 696, 536 234, 4353201, 435375, 435328

Abstract:

The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with FcγR and which allow for the inclusion and targeting of a second protein domain to cells expressing FcγR. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgGfused to the framework region of human IgG. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of FcγR in autoimmune disorders.